{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:15:26Z","timestamp":1790187326019,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"37","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2023,9,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The BH3-mimetic drug Venetoclax, a specific inhibitor of anti-apoptotic BCL-2, has had clinical success for the treatment of chronic lymphocytic leukaemia and acute myeloid leukaemia. Attention has now shifted towards related pro-survival BCL-2 family members, hypothesising that new BH3-mimetic drugs targeting these proteins may emulate the success of Venetoclax. BH3-mimetics targeting pro-survival MCL-1 or BCL-XL have entered clinical trials, but managing on-target toxicities is challenging. While increasing evidence suggests BFL-1\/A1 is a resistance factor for diverse chemotherapeutic agents and BH3-mimetic drugs in haematological malignancies, few studies have explored the role of BCL-W in the development, expansion, and therapeutic responses of cancer. Previously, we found that <jats:italic>BCL-W<\/jats:italic> was not required for the ongoing survival and growth of various established human Burkitt lymphoma and diffuse large B cell lymphoma cell lines. However, questions remained about whether BCL-W impacts lymphoma development. Here, we show that BCL-W appears dispensable for MYC-driven lymphomagenesis, and such tumours arising in the absence of BCL-W show no compensatory changes to BCL-2 family member expression, nor altered sensitivity to BH3-mimetic drugs. These results demonstrate that BCL-W does not play a major role in the development of MYC-driven lymphoma or the responses of these tumours to anti-cancer agents.<\/jats:p>","DOI":"10.1038\/s41388-023-02804-5","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T18:02:23Z","timestamp":1691776943000},"page":"2776-2781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["BCL-W makes only minor contributions to MYC-driven lymphoma development"],"prefix":"10.1038","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1946-5161","authenticated-orcid":false,"given":"Sarah T.","family":"Diepstraten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6442-9947","authenticated-orcid":false,"given":"John E.","family":"La Marca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-4231","authenticated-orcid":false,"given":"Savannah","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5020-4891","authenticated-orcid":false,"given":"Andreas","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-1201","authenticated-orcid":false,"given":"Gemma L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"2804_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2804_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","volume":"7","author":"K Nakano","year":"2001","unstructured":"Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7:683\u201394.","journal-title":"Mol Cell"},{"key":"2804_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","volume":"288","author":"E Oda","year":"2000","unstructured":"Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053\u20138.","journal-title":"Science"},{"key":"2804_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1097-2765(01)00213-1","volume":"7","author":"J Yu","year":"2001","unstructured":"Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell. 2001;7:673\u201382.","journal-title":"Mol Cell"},{"key":"2804_CR5","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.3390\/cancers13133257","volume":"13","author":"A Lees","year":"2021","unstructured":"Lees A, Sessler T, McDade S. Dying to Survive-The p53 Paradox. Cancers (Basel). 2021;13:3257.","journal-title":"Cancers (Basel)"},{"key":"2804_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","volume":"28","author":"D Kaloni","year":"2023","unstructured":"Kaloni D, Diepstraten ST, Strasser A, Kelly GL. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis 2023;28:20\u201338.","journal-title":"Apoptosis"},{"key":"2804_CR7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nrd2658","volume":"7","author":"G Lessene","year":"2008","unstructured":"Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7:989\u20131000.","journal-title":"Nat Rev Drug Discov"},{"key":"2804_CR8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677\u201381.","journal-title":"Nature"},{"key":"2804_CR9","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421\u20138.","journal-title":"Cancer Res"},{"key":"2804_CR10","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007;128:1173\u201386.","journal-title":"Cell"},{"key":"2804_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","volume":"14","author":"H Zhang","year":"2007","unstructured":"Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14:943\u201351.","journal-title":"Cell Death Differ"},{"key":"2804_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41420-021-00505-0","volume":"7","author":"S Arulananda","year":"2021","unstructured":"Arulananda S, O'Brien M, Evangelista M, Jenkins LJ, Poh AR, Walkiewicz M, et al. A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discov. 2021;7:122.","journal-title":"Cell Death Discov"},{"key":"2804_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"2804_CR14","doi-asserted-by":"publisher","first-page":"1005659","DOI":"10.3389\/fonc.2022.1005659","volume":"12","author":"J Liu","year":"2022","unstructured":"Liu J, Chen Y, Yu L, Yang L. Mechanisms of venetoclax resistance and solutions. Front Oncol. 2022;12:1005659.","journal-title":"Front Oncol"},{"key":"2804_CR15","doi-asserted-by":"publisher","first-page":"380","DOI":"10.20517\/cdr.2021.125","volume":"5","author":"F Ong","year":"2022","unstructured":"Ong F, Kim K, Konopleva MY. Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist. 2022;5:380\u2013400.","journal-title":"Cancer Drug Resist"},{"key":"2804_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","volume":"22","author":"ST Diepstraten","year":"2022","unstructured":"Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022;22:45\u201364.","journal-title":"Nat Rev Cancer"},{"key":"2804_CR17","first-page":"665","volume":"13","author":"L Gibson","year":"1996","unstructured":"Gibson L, Holmgreen S, Huang D, Bernard O, Copeland N, Jenkins N, et al. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 1996;13:665\u201375.","journal-title":"Oncogene"},{"key":"2804_CR18","doi-asserted-by":"publisher","first-page":"12424","DOI":"10.1073\/pnas.95.21.12424","volume":"95","author":"CG Print","year":"1998","unstructured":"Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A, Wreford N, et al. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci USA. 1998;95:12424\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2804_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ng0398-251","volume":"18","author":"AJ Ross","year":"1998","unstructured":"Ross AJ, Waymire KG, Moss JE, Parlow AF, Skinner MK, Russell LD, et al. Testicular degeneration in Bclw-deficient mice. Nat Genet. 1998;18:251\u20136.","journal-title":"Nat Genet"},{"key":"2804_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0303-7207(00)00257-4","volume":"165","author":"W Yan","year":"2000","unstructured":"Yan W, Suominen J, Samson M, J\u00e9gou B, Toppari J. Involvement of Bcl-2 family proteins in germ cell apoptosis during testicular development in the rat and pro-survival effect of stem cell factor on germ cells in vitro. Mol Cell Endocrinol. 2000;165:115\u201329.","journal-title":"Mol Cell Endocrinol"},{"key":"2804_CR21","first-page":"1093","volume":"63","author":"HW Lee","year":"2003","unstructured":"Lee HW, Lee SS, Lee SJ, Um HD. Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase\/c-Jun NH2-terminal kinase activation. Cancer Res. 2003;63:1093\u2013100.","journal-title":"Cancer Res"},{"key":"2804_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1054\/bjoc.1999.0897","volume":"82","author":"JW Wilson","year":"2000","unstructured":"Wilson JW, Nostro MC, Balzi M, Faraoni P, Cianchi F, Becciolini A, et al. Bcl-w expression in colorectal adenocarcinoma. Br J Cancer. 2000;82:178\u201385.","journal-title":"Br J Cancer"},{"key":"2804_CR23","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-17-1144","volume":"23","author":"CM Adams","year":"2017","unstructured":"Adams CM, Mitra R, Gong JZ, Eischen CM. Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. Clin Cancer Res. 2017;23:7119\u201329.","journal-title":"Clin Cancer Res"},{"key":"2804_CR24","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41375-019-0611-9","volume":"34","author":"CM Adams","year":"2020","unstructured":"Adams CM, Mitra R, Vogel AN, Liu J, Gong JZ, Eischen CM. Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma. Leukemia 2020;34:947\u201352.","journal-title":"Leukemia"},{"key":"2804_CR25","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1172\/JCI89486","volume":"127","author":"CM Adams","year":"2017","unstructured":"Adams CM, Kim AS, Mitra R, Choi JK, Gong JZ, Eischen CM. BCL-W has a fundamental role in B cell survival and lymphomagenesis. J Clin Investig. 2017;127:635\u201350.","journal-title":"J Clin Investig"},{"key":"2804_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/bloodadvances.2019000541","volume":"4","author":"ST Diepstraten","year":"2020","unstructured":"Diepstraten ST, Chang C, Tai L, Gong JN, Lan P, Dowell AC, et al. BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines. Blood Adv. 2020;4:356\u201366.","journal-title":"Blood Adv"},{"key":"2804_CR27","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/onc.2008.466","volume":"28","author":"LJ Beverly","year":"2009","unstructured":"Beverly LJ, Varmus HE. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene 2009;28:1274\u20139.","journal-title":"Oncogene"},{"key":"2804_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1101\/gad.182980.111","volume":"26","author":"SP Glaser","year":"2012","unstructured":"Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26:120\u20135.","journal-title":"Genes Dev"},{"key":"2804_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1084\/jem.167.2.353","volume":"167","author":"AW Harris","year":"1988","unstructured":"Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167:353\u201371.","journal-title":"J Exp Med"},{"key":"2804_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32485-9","volume":"13","author":"Y Deng","year":"2022","unstructured":"Deng Y, Diepstraten ST, Potts MA, Giner G, Trezise S, Ng AP, et al. Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance. Nat Commun. 2022;13:4739.","journal-title":"Nat Commun"},{"key":"2804_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 2016;538:477\u201382.","journal-title":"Nature"},{"key":"2804_CR32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/318533a0","volume":"318","author":"JM Adams","year":"1985","unstructured":"Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533\u20138.","journal-title":"Nature"},{"key":"2804_CR33","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/nm.f.1895","volume":"14","author":"MM Matzuk","year":"2008","unstructured":"Matzuk MM, Lamb DJ. The biology of infertility: research advances and clinical challenges. Nat Med. 2008;14:1197\u2013213.","journal-title":"Nat Med"},{"key":"2804_CR34","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.1073\/pnas.0701669104","volume":"104","author":"H Zheng","year":"2007","unstructured":"Zheng H, Stratton CJ, Morozumi K, Jin J, Yanagimachi R, Yan W. Lack of Spem1 causes aberrant cytoplasm removal, sperm deformation, and male infertility. Proc Natl Acad Sci USA. 2007;104:6852\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2804_CR35","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41418-017-0045-8","volume":"25","author":"M Mensink","year":"2018","unstructured":"Mensink M, Anstee NS, Robati M, Schenk RL, Herold MJ, Cory S, et al. Anti-apoptotic A1 is not essential for lymphoma development in E\u00b5-Myc mice but helps sustain transplanted E\u00b5-Myc tumour cells. Cell Death Differ. 2018;25:797\u2013808.","journal-title":"Cell Death Differ"},{"key":"2804_CR36","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2006-10-051847","volume":"109","author":"PN Kelly","year":"2007","unstructured":"Kelly PN, Puthalakath H, Adams JM, Strasser A. Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma. Blood 2007;109:4907\u201313.","journal-title":"Blood"},{"key":"2804_CR37","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.celrep.2016.02.039","volume":"14","author":"S Grabow","year":"2016","unstructured":"Grabow S, Delbridge AR, Aubrey BJ, Vandenberg CJ, Strasser A. Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis. Cell Rep. 2016;14:2337\u201347.","journal-title":"Cell Rep."},{"key":"2804_CR38","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.1182\/blood-2011-07-367672","volume":"118","author":"PN Kelly","year":"2011","unstructured":"Kelly PN, Grabow S, Delbridge AR, Strasser A, Adams JM. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. Blood 2011;118:6380\u20136.","journal-title":"Blood"},{"key":"2804_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05815-z","volume":"9","author":"RS Soderquist","year":"2018","unstructured":"Soderquist RS, Crawford L, Liu E, Lu M, Agarwal A, Anderson GR, et al. Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity. Nat Commun. 2018;9:3513.","journal-title":"Nat Commun"},{"key":"2804_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2417-0","volume":"11","author":"ML Hartman","year":"2020","unstructured":"Hartman ML, Czyz M. BCL-w: apoptotic and non-apoptotic role in health and disease. Cell Death Dis. 2020;11:260.","journal-title":"Cell Death Dis"},{"key":"2804_CR41","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41418-023-01117-0","volume":"30","author":"ST Diepstraten","year":"2023","unstructured":"Diepstraten ST, Young S, La Marca JE, Wang Z, Kluck RM, Strasser A, et al. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs. Cell Death Differ. 2023;30:1005\u201317.","journal-title":"Cell Death Differ"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-023-02804-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-023-02804-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-023-02804-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T11:03:15Z","timestamp":1694170995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-023-02804-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":41,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2023,9,8]]}},"alternative-id":["2804"],"URL":"https:\/\/doi.org\/10.1038\/s41388-023-02804-5","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"29 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employees of WEHI which receives milestone and royalty payments related to Venetoclax. AS and GLK have in the past received research funding from Servier.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}